Frequently asked questions on the European Shortages Monitoring Platform (ESMP)

Human medicines European public assessment report (EPAR): Pradaxa, dabigatran etexilate, Date of authorisation: 17/03/2008, Revision: 45, Status: Authorised

Human medicines European public assessment report (EPAR): Ngenla, somatrogon, Date of authorisation: 14/02/2022, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Matever, levetiracetam, Date of authorisation: 03/10/2011, Revision: 29, Status: Authorised

Human medicines European public assessment report (EPAR): Seffalair Spiromax, salmeterol,fluticasone propionate, Date of authorisation: 26/03/2021, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Omforro, midazolam, Status: Application withdrawn

European Shortages Monitoring Platform (ESMP): Interoperability with national and pharmaceutical industry systems

Quality Review of Documents (QRD) working group plenary meeting dates

Human medicines European public assessment report (EPAR): Erelzi, etanercept, Date of authorisation: 23/06/2017, Revision: 19, Status: Authorised

European Shortages Monitoring Platform (ESMP): Guidance, training materials and events